Evidence map›Paper›PMID 40921928›Full record

ArticleClinical and experimental nephrology2025

Comparison of renal effects between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension and chronic kidney disease in Japan.

Mari Sotozawa, Kyoji Chiba, Kazuo Kobayashi, Keiichi Chin, Hideo Shimura, Toshinao Tsuge, Shun Ito, Hiroyuki Sakai, Takayuki Furuki, Atsushi Matsuzaki and 10 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mari Sotozawa *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kyoji Chiba *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kazuo KobayashiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. k-taishi@xc4.so-net.ne.jp.ORCID http://orcid.org/0000-0002-1284-9728
Keiichi ChinCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Hideo ShimuraCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Toshinao TsugeCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Shun ItoCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Hiroyuki SakaiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Takayuki FurukiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Atsushi MatsuzakiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Shinichi NakajimaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Nobukazu TakadaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Hareaki YamamotoCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Hiroshi TakedaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Takamasa IwasawaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Togo AoyamaDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara, Japan.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Akira KanamoriCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1Fujimicho naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Hiromichi WakuiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSacubitril/valsartan is typically prescribed for patients with heart failure and hypertension. We previously reported that sacubitril/valsartan provides comparable blood pressure (BP) reduction and superior tolerability compared to thiazide diuretics. This post hoc study aimed to compare the effects of sacubitril/valsartan and thiazide diuretics in patients with chronic kidney disease (CKD).

methodsAmong patients with poorly controlled BP in the office or at home despite combination therapy with renin-angiotensin system (RAS) inhibitors and calcium channel blockers, 611 patients were included: those treated with thiazide diuretics (THZ group) and those who were switched from RAS inhibitors to sacubitril/valsartan for the next 12 months. After implementing multiple methods, 505 patients with CKD (n = 211 in the THZ group and n = 294 in the SacVal group) were analyzed using propensity score analysis with inverse probability weighting.

resultCompared to the THZ group, the SacVal group demonstrated significantly reduced systolic office BP, uric acid, and glycated hemoglobin A

conclusionCompared to the addition of thiazide diuretics, the transition to sacubitril/valsartan resulted in greater BP reduction and more favorable changes in uric acid, HbA

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsHypertensionKidneyRenal Insufficiency, ChronicSodium Chloride Symporter InhibitorsTetrazolesValsartanAgedBiphenyl CompoundsBlood PressureDrug CombinationsFemaleGlomerular Filtration RateGlycated HemoglobinAminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug CombinationsGlycated Hemoglobinhemoglobin A1c protein, humansacubitril and valsartan sodium hydrate drug combinationSodium Chloride Symporter InhibitorsTetrazolesUric AcidValsartanCombination treatmentSacubitril/valsartanThiazide diuretics

Identifiers

PMID40921928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.